Thoughts after the 2021 Annual meeting: Cytodyn
Post# of 155002
(Total Views: 861)
Posted On: 11/24/2021 1:24:03 PM
Thoughts after the 2021 Annual meeting:
Cytodyn has persevered through many obstacles such as:
needing to gather more HIV data for the FDA years ago,
the incompetence and harmful roadblocks of Amarex, and
the egoism & conflicts of interest from an attempted hostile board takeover.
All annual meeting ballot points were approved by the shareholders today, including an increase to the authorized shares which allows the company a tool to raise funds when needed.
Human trial data has been gathered across multiple diseases (HIV, Covid19, NASH, Breast Cancer, Colo-rectal Cancer, Pancreatic Cancer, etc. The potential for many symbiotic partnerships is strong.
The company now mentions that the scope of where the drug may be useful has increased over the years from a small segment of the HIV patient population to now 32 separate diseases including Auto-Immune conditions, Cancer, Covid19, NASH, etc. The potential drug market size has increased from $30 million to $125 Billion.
The company has wisely defended it's intellectual property, defended itself from a hostile takeover attempt, diversified it's use of CRO's, diversified it's trials into other countries, diversified it's regulatory approval into other countries, and secured production.
All these are signs of a tenacious team which continues to display that they have a fire in their belly that will bring them to the finish line IMO
Cytodyn has persevered through many obstacles such as:
needing to gather more HIV data for the FDA years ago,
the incompetence and harmful roadblocks of Amarex, and
the egoism & conflicts of interest from an attempted hostile board takeover.
All annual meeting ballot points were approved by the shareholders today, including an increase to the authorized shares which allows the company a tool to raise funds when needed.
Human trial data has been gathered across multiple diseases (HIV, Covid19, NASH, Breast Cancer, Colo-rectal Cancer, Pancreatic Cancer, etc. The potential for many symbiotic partnerships is strong.
The company now mentions that the scope of where the drug may be useful has increased over the years from a small segment of the HIV patient population to now 32 separate diseases including Auto-Immune conditions, Cancer, Covid19, NASH, etc. The potential drug market size has increased from $30 million to $125 Billion.
The company has wisely defended it's intellectual property, defended itself from a hostile takeover attempt, diversified it's use of CRO's, diversified it's trials into other countries, diversified it's regulatory approval into other countries, and secured production.
All these are signs of a tenacious team which continues to display that they have a fire in their belly that will bring them to the finish line IMO
(36)
(0)CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.